Latest News
Conference Coverage
Apremilast beats placebo in early PsA affecting few joints
Phase 4 trial offers insight into efficacy in patients whose mild cases have gotten less research attention.
Conference Coverage
TNF blockers not associated with poorer pregnancy outcomes
Patients with rheumatic disease who continued TNF blockers during their pregnancy did not have an increased risk of worse fetal and maternal...
Conference Coverage
Caution raised on reduced-dose steroids in rare vasculitides GPA, MPA
A real-world analysis finds that some patients who receive reduced-dose glucocorticoids may have a higher risk of poor outcomes.
Conference Coverage
Pregnancy in rheumatic disease quadruples risk of cardiovascular events
Pregnant patients with lupus and concomitant APS had an 18-fold higher risk for a cardiovascular event during and up to 6 weeks postpartum than...
Conference Coverage
Pregnancies with low anti-SSA/Ro autoantibody levels: Forgo fetal heart rhythm monitoring?
The ongoing prospective multicenter trial is the largest of its kind.
Conference Coverage
Alpha-gal syndrome: Red meat is ‘just the beginning,’ expert says
“We are seeing increasing diagnoses of AGS in places that are not, perhaps, where we first thought this allergy existed.”
Conference Coverage
Obinutuzumab promotes renal preservation in lupus nephritis
A post hoc analysis of the NOBILITY trial showed improved outcomes for patients taking obinutuzumab (Gazyva), compared with placebo.
From the Journals
Short steroid taper tested with tocilizumab for giant cell arteritis
Results from a pilot study examining a shortened prednisone taper of 8 weeks’ length rather than 26 weeks suggest it may be possible to reduce...
Conference Coverage
CPPD nomenclature is sore subject for gout group
G-CAN hopes to standardize terminology and finally oust ‘pseudo’ vernacular.
From the Journals
Long COVID and mental illness: New guidance
“Long COVID is real, and mental health conditions do not cause long COVID.”
Conference Coverage
Gout: Studies support early use of urate-lowering therapy, warn of peripheral arterial disease
Urate-lowering drugs might be OK early on; gout may boost peripheral arterial disease.